Longeveron to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
Longeveron to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
MIAMI, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report third quarter 2024 financial results and provide a business update on Tuesday, November 12, 2024 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET.
2024年11月4日，迈阿密（GLOBE NEWSWIRE）——Longeveron Inc.（纳斯达克：LGVN），一家临床阶段的再生医学生物技术公司，正在开发用于危及生命和慢性老化相关疾病的细胞疗法，今天宣布将于2024年11月12日星期二美国金融市场收盘后公布2024年第三季度财务业绩，并提供业务更新。该公司将于当天下午4:30在东部时间举行电话会议并通过网络直播。
Conference Call Details:
电话会议详情：
| Conference Call Number: | 1.877.407.0789 |
| Conference ID: | 13749428 |
| Call me Feature: | Click Here |
| Webcast: | Click Here |
| 电话会议号码： | 1.877.407.0789 |
| 会议ID： | 13749428 |
| 看涨我的特征: | 点击这里 |
| 网络直播： | 点击这里 |
An archived replay of the webcast will be available on the "Events & Presentations" section of the Company's website following the conference.
公司网站的“事件与演示”部分将在会议结束后提供网络研讨会的存档回放。
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company's lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer's Disease (AD), and Aging-related Frailty. Lomecel-B development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit or follow Longeveron on LinkedIn, X, and Instagram.
关于Longeveron Inc.：
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company's lead investigational product is Lomecel-b, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-b has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer's Disease (AD), and Aging-related Frailty. Lomecel-b development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit or follow Longeveron on LinkedIn, X, and Instagram.
Investor Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
投资者联系人：
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
